Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Moodys
McKinsey
McKesson
Mallinckrodt

Last Updated: December 3, 2022

Details for Patent: 7,737,181


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 7,737,181 protect, and when does it expire?

Patent 7,737,181 protects DIFFERIN and is included in one NDA.

This patent has thirty-nine patent family members in twenty-two countries.

Summary for Patent: 7,737,181
Title:Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Abstract:Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions.
Inventor(s): Graeber; Michael (Lawrenceville, NJ), Czernielewski; Janusz (Boit, FR)
Assignee: Galderma Research & Development (Biot, FR)
Application Number:11/494,693
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Formulation;

Drugs Protected by US Patent 7,737,181

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Galderma Labs Lp DIFFERIN adapalene GEL;TOPICAL 021753-001 Jun 19, 2007 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,737,181

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France02 03070Mar 12, 2002

International Family Members for US Patent 7,737,181

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 038924 See Plans and Pricing
Austria 417610 See Plans and Pricing
Austria 432072 See Plans and Pricing
Australia 2003216898 See Plans and Pricing
Australia 2008203279 See Plans and Pricing
Brazil 0307550 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Express Scripts
Harvard Business School
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.